Targeting the ubiquitin pathway for cancer treatment

Area of Science:

• Biochemistry
• Molecular Biology
• Oncology

Background:

• Proteasome-mediated degradation maintains cellular protein homeostasis.
• Dysregulated degradation in cancer leads to oncoprotein stabilization or tumor suppressor loss.
• E3 ubiquitin ligases are crucial for substrate targeting in this pathway.

Purpose of the Study:

• To review the ubiquitin pathway components as potential anti-cancer drug targets.
• To highlight E3 ubiquitin ligases, including SCF types, as therapeutic targets.
• To discuss bioactive compounds targeting the ubiquitin pathway for cancer treatment.

Main Methods:

• Literature review of the ubiquitin-proteasome system.
• Analysis of E1, E2, E3 enzymes, and deubiquitinating enzymes (DUBs).
• Survey of existing bioactive compounds targeting the ubiquitin pathway.

Main Results:

• The ubiquitin pathway, including E1, E2, E3s, and DUBs, presents multiple drug targets.
• E3 ubiquitin ligases, particularly SCF complexes, are key regulators in cancer.
• Various bioactive compounds targeting this pathway show potential in cancer control.

Conclusions:

• Targeting the ubiquitin-proteasome system offers a viable strategy for novel cancer therapeutics.
• Modulating E3 ubiquitin ligase activity is critical for cancer treatment.
• Further research into bioactive compounds can lead to effective anti-cancer drugs.